Pfizer (PFE)

Cash & Short-Term Investments

$11.70B

Quarterly · Period ending: · USD

PFE logo

PFE Cash & Short-Term Investments

Latest reported$11.70B
PFE Quarterly Cash & Short-Term Investments ($412.60M → $11.70B)
High-resolution chart · PNG

PFE cash & short-term investments history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Pfizer Cash & Short-Term Investments — Quarterly (USD)
Period endingCash & Short-Term Investments (USD)
11,699,000,000
13,075,000,000
13,596,000,000
14,984,000,000
13,249,000,000
17,316,000,000
20,477,000,000
9,952,000,000
7,101,000,000
11,929,000,000
12,690,000,000
44,181,000,000
44,785,000,000
19,972,000,000
22,732,000,000
36,123,000,000
33,304,000,000
23,897,000,000
31,069,000,000
29,696,000,000
21,700,000,000
13,667,000,000
12,223,000,000
10,499,000,000
11,394,000,000
10,351,000,000
9,646,000,000
9,087,000,000
12,911,000,000
11,619,000,000
18,833,000,000
17,239,000,000
13,431,000,000
11,421,000,000
19,992,000,000
16,925,000,000
14,333,000,000
14,560,000,000
17,850,000,000
14,371,000,000
20,942,000,000
19,443,000,000
23,290,000,000
20,658,000,000
30,256,000,000
27,708,000,000
36,122,000,000
33,446,000,000
34,054,000,000
33,881,000,000
32,408,000,000
33,679,000,000
33,711,000,000
35,346,000,000
32,399,000,000
22,968,000,000
24,306,000,000
23,972,000,000
26,452,000,000
28,963,000,000
25,484,000,000
24,009,000,000
28,012,000,000
22,464,000,000
19,268,000,000
17,262,000,000
25,969,000,000
52,473,000,000
49,647,000,000
34,052,000,000
23,731,000,000
26,017,000,000
26,179,000,000
28,628,000,000
25,475,000,000
22,298,000,000
22,253,000,000
22,470,000,000
27,713,000,000
12,831,000,000
14,750,000,000
15,502,000,000
22,226,000,000
13,389,000,000
14,569,000,000
21,971,000,000
19,893,000,000
18,678,000,000
17,483,000,000
13,952,000,000
11,952,000,000
14,417,000,000
15,957,000,000
15,505,000,000
12,551,000,000
12,544,000,000
11,336,000,000
9,893,000,000
8,615,000,000
9,463,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.